local_hospital

Deutsches Zentrum für Neurodegenerative Erkrankungen e. V.

Address
Venusberg-Campus 1, Gebäude 99, 53127 Bonn, Germany

Site Overview

assignment
1
connected trial
corporate_fare
1
sponsor
science
0
IMPs

Activity Indicator

Last 6 months

1
Trials started
New activity detected vs previous period.
0
Trials started 6–12 months ago
1
Total trials linked
Low Activity
trending_upGrowing+100%
1
Mar
Apr
May
Jun
Jul
Aug

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
1
Active sponsors
1

Sponsor Network

Top 1 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
1
Outperforms 2% of sites
public
Therapeutic diversity
1areas
Outperforms 2% of sites
groups
Sponsor diversity
1sponsors
Outperforms 2% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Deutsches Zentrum für Neurodegenerative Erkrankungen e. V.

Trial Sponsor Phase Status Start Date End Date
Phase 2/3 Randomized, Double‑Blind, Placebo‑Controlled, Dose‑Ranging Study of SKY‑0515 in Adults with Huntington’s DiseaseSkyhawk Therapeutics Inc.Phase IVNot Yet Recruiting

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.